Комбинированное применение химиотерапии и моноклональных антител к антигену В-клеток CD20 (Ритуксимаба) в терапии В-клеточных неходжкинских лимфом у детей и подростков
Диссертация
При выполнении протокола наблюдается замедленный темп регрессии опухолевых образований, за исключением больных с В-клеточным зрелоклеточным лейкозом (из 24 больных, закончивших протокол, ремиссия достигнута в более ранние сроки (после 3 курсов ПХТ) у 22 пациентов (91,6%)) в отличие от пациентов с ЛБ и ДВККЛ, что может говорить о более быстром клиренсе опухолевых клеток из костного мозга, чем… Читать ещё >
Список литературы
- Кисляк Н.С., Таболин В. А., под редакцией.," Гематология детского возраста", М., 2-ой МОЛГМИ им. Пирогова, 1987,-102-
- Кондратенко И.В., Кузнецова" М.А и др.: «Злокачественные новообразования у больных с атаксией-телеангиоэктазией». Вопросы гематологии/онкологии и" иммунопатологии в педиатрии"2002' г., томГ,№ 1,с 44−47
- Новик А., А., Мельниченко’В?.Я. и др. «Характеристика некоторых цитогенетических показателей при неходжкинских лимфомах», «Гематология и трансфузиология"2000,№ 3, с.50-
- Островская» А.В."Характеристика и результаты терапии неходжкинских лимфом по- данным моноцентрового исследования"-Диссертация канд. Мед. наук, 2004 г.
- Поддубная И.В.: Обоснование лечебной^ тактики при неходжкинских лимфомах" «Современная онкология», 2002,№ 1,том.4,с: 3−7-
- Резник И.Б., Тогоев О. О., Контдратенко И. В. и др. «Молекулярные и иммунные дефекты при синдроме хромосомных поломок Ниймеген», «Гематология и трансфузиология 1999 г., № 6, с.48-
- Самочатова Е.В., Алейникова^ О.В., Беликова Л. Ю. и др.» Неходжкинские лимфомы у детей: клиническая характеристика, возможности диагностики и терапии- по данным клиник России'- и Беларуси", «Гематология и трансфузиология», 2001,№Г, с. З-
- Самочатова Е.В., Островская A.B., Карачунский А. И. и др. «Значение верификации варианта неходжкинских лимфом у детей для эффективности лечения по современным протоколам» «Гематологи и трансфузиология», 2000 г., № 6,с.29−30-
- Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000−403:503−511.
- Anderson JR., Jenkin RD, Wilson JF, et al. Long-term followup of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551from the Childrens Cancer Group. J Clin Oncol. 1993−11: 1024−1032.
- Armitage JO- Vose JM, Linder J, et al: Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin. Oncol. 7:1783−1790, 1989
- Atra A, Gerrard M, Hobson R, et al. Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol.2001- 112: 965−968.
- Atra A, Imeson JD, Hobson R, et al. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma* (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer. 2000−82: 1396−1402.
- Attias D, Weitzman S: The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: A review of available evidence. Curr. Opin. Pediatr 20:17−22, 2008
- Barnacle A M, McHugh K. Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy. Pediatr. Blood Cancer. 2006 Feb- 46(2): 127−34.
- Bieniman K., Meinhardt A. et al: Non-Hodgkin"s lymphoma in children with chromosomal breakage syndromes (AT and NBS) A experience from the NHL -BFM trials |74|Hematology Meeting Reports 2009−3(5) —
- Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage" EV small noncleaved-cell* lymphoma: a Pediatric Oncology Group study, J'' Clin Oncol. 1996- 14:12 521 261.
- BrilLN.E. Generalized giant lymph*, follicile hyperplasia of lymph nodes and spleen. A hitherto underscribe type: J: Amer.Med.Ass.-1925.-vol.84№ 9-p.668−671-
- Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005−131:39−49.
- Burkitt D. A sarcoma involving the jaw in* African children: Br. J. Surg.-1985-№ 46-p.2
- Cairo M. S, R. Sposto, M. Gerrad et al Risk factors associated with poor outcome in children and adolescents with mature B-NHL: report of the FAB/LMB96 study |20|Hematology Meeting Reports 2009−3(5) —
- Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007- 109:2736−2743.
- Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B
- Cavali F., Armitage J.O., et al:"Annual' of Lymphoid Malignancies" Martin Dunitz Ltd., 2001,-175-
- Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-celL markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol-. 2004−28: 464−470-
- Cohen J.I."EBV Infection", N Eng JMed, Med, 200, Augl7,v.343:481
- Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927−1932, 1998
- Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235−242, 2002
- Coiffier B: State-of-the-art therapeutics: Diffuse large B-cell lymphoma. J Clin Oncol 23:6387- 6393, 2005 '
- Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation1 profile assessed’by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003- 101:78−84-
- Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in’childhood acute lymphoblastic leukemia. Blood. 2002−100:52−58-.
- Czuczman MS, Grillo-Lope AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268−276, 1999
- Dave BJ, Weisenburger DD, Higgins CM, et al. Cytogenetics and fluorescence in situ hybridization studies of diffuse large B-cell lymphoma in children and young adults. Cancer Genet Cytogenet. 2004- 153:115−121.
- Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006−354: 2431−2442.
- Dunleavy K, Pittaluga S, Janik J, et al: Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: Preliminary results showing excellent outcome. Blood 108, 2006 (abstr 2736)
- Fields KK, Zorsky PE, Hiemenz JW, Kronish LE, Elfenbein GJ. Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity. J Clin Oncol. 1994−12:544−552.
- Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins, SL. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma* and diffuse large B-cell lymphoma. Am J Clin Pathol. 2004−121:384−392.
- Gerrard M- Cairo
- Gerrard M, Cairo MS, Weston G, et al. Results of the FAB LMB 96 international study in children and adolescents (C+A) with localised, resected B cell lymphoma (large cell LCL., Burkitt’s [BL], and Burkitt-like [BLL]). J Clin 0ncol:2003- 22:795.
- Gong Q, Ou Q, Ye S, et al: Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174:817−826, 2005
- Greenwood M. A report on the natural duration of cancer. Rep Public Health Med Subj.1926- 33:1−26-
- Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121−3127, 2006
- Hainsworth JD: Safety of rituximab in the treatment of B cell malignancies: implication for rheumatoid arthritis: Arthritis Res.Ther.2003 -5(4), 12−16
- Haioun C, Itti E, Rahmouni A, et al. 18 °F.fluoro-2-deoxy-Dglucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005−106:1376−1381.
- Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification* of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004−103:275−282.
- Harjunpa" A, WiklundtT, Collan J, et al: Complement activation in circulation’and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 42:731−738,2001
- Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361−1364, 1994-
- Hecht J., Aster J. Molecular biology of Burkitt’s lymphoma: J. Clin. Oncology. -2000-v.l8,p.3703−3721-
- Hummel M, Bentink S, Berger H, et al. A biologie definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006−354: 2419−2430.
- Hutchison RE, Berard CW, Shuster JJ, et al: B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: A Pediatric Oncology Group study. J Clin Oncol* 13:2023−2032, 1995
- Hutchison RE, Fairclough DL, Holt H, et al: Clinical significance of histology and immunophenotype in childhood diffuse large cell lymphoma. Am J Clin Pathol 95:787−793, 1991
- Hvizdala EV, Berard C, Callihan T, et al: Nonlymphoblastic lymphoma in children- histology and stage-related response to therapy: A Pediatric Oncology Group study. J Clin Oncol 9:1189−1195, 1991
- Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defines a unique tumor subset within the* germinal center B-cell-like diffuse large B-ceir lymphoma. AmPathol. 2004- 165:159- 166.
- Jaffe ES, Harris NL, Stein H, et al (eds): WHO Classification: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
- Janas E, Priest R, Wilde JI, et al: Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Glin Exp Immunol 139:439−446, 2005
- Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention. Oncogene 24:2121−2143, 2005
- Junshik Hong, Yukyung Lee et al. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma, annals of Hematology: 10.1007/s00277−011−1353−6)
- Kellenberger CJ, Miller SF, Khan M, Gilday DL, Weitzman S, Babyn PS. Initial experience with FSE STIR* whole-body MR imaging for staging lymphoma in children. Eur Radiol. 2004 Oct- 14(10): 1829−41.
- Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456−473, 2005
- Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and’MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998- 92:3152−3162.
- Laver JH, Mahmoud H, Pick TE, et al: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: A Pediatric Oncology Group Study. Leuk Lymphoma 42:399−405, 2001
- Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene,
- BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001−98:945−951.85. lstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003−101:3875−3876.
- Lukes R., Collins R.: «New approaches to the Classification of Lymphoma» Br. J. Cancer, 1975, v.31(suppl.), 1−28-
- Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996−14:925−934.
- Magrath I.T.," Molecular Characteristics of Diffuse Large-B-Cell Lymphoma", N.Engl.J. Med, June 20,2002−346(25):1998−1999-
- Magrath IT: Malignant non-Hodgkin's lymphomas in children. Hematol Oncol Clin North Am 1:577−602, 1987
- Miles* R, Raphael^ M, McCarthy K, et al. Diffuse large B-cell lymphomas in pediatric patients demonstrate a marked predominance of germinal center cell phenotype. Ann Oncol. 2005(suppl 5):61.
- Moon L, McHugh K. Advances in paediatric tumour imaging. Arch Dis Child. 2005 Jun- 90(6):608-l 1.
- Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2- associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).Blood l 01:4279−4284, 2003
- Murphy SB, Fairclough DL, Hutchison RE, et al: Non-Hodgkin's lymphomas of childhood: An analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 7:186−193, 1989
- O’Brien SM, Kantarjian H, Thomas- DA, et al: Rituximab- dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165−2170- 2001
- O’Conor G. Malignant lymphoma in African children. A pathology entity: Cancer 1961, v. l4,p.270−283-
- Onciu M, Schlette E, Zhou Y, et al. Secondary chromosomal abnormalities predict outcome1 in pediatric and adult highstage Burkitt lymphoma. Cancer. 2006−107:1084−1092.
- Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma- in pediatric patients predominantly belong to the germinal-center type B-cell lymphomas. Blood. 2006- 107:4047−4052.
- Patte C, Laplanche A, Bertozzi AI, et al. Granulocyte colonystimulating factor in induction treatment ofs children with non^ Hodgkin’s lymphoma: a randomized study of the French’Society of Pediatric Oncology. J Clin Oncol. 2002−20:441−448.
- Patte C: Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Haematol 15:695−711, 2002
- Perkins S: B-cell non-Hodgkin lymphoma (NHL) in children and adolescents. Ann Oncol, 2002
- Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients withaggressive CD20 B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105−116, 2008
- Pillon M, Di Tullio MT, Garaventa A, et al. Longterm results of theifirst Italian Association of Pediatric Hematology and- Oncology protocol for" the treatment of pediatric B-celh non-Hodgkin lymphoma (AIEOP LNH92). Cancer. 2004−101:385−394.
- Purtilo D., Manolov G. et al: 'Role of EBV in the etiology of Burkitt’s lymphoma" IARC Sci. Publ., 1985-(60)231−247-
- Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999−94:3294−3306.
- Reiter A. Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma Hematology 2007
- Rosenberg S.A., Berard C.W., Brown B.W. et al: National Cancer Institute Sponsored Study of Classification of NHL, Cancer 1982−49(10):2112−35:
- Rosenwald A, Wright G, Chan WC, et al. The use of molecularprofiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002−346: 1937−1947,
- Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003−198:851−862.
- Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003−3:185−197.
- Rubenstein JL, Combs D, Rosenberg J, et al: Rituximab therapy for CNS Lymphoma Blood 101:466−468, 2003
- Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS-involvement in childhood and adolescent non-Hodgkin lymphoma differ according to NHL subtype—a BFM group report. J Clin Oncol. 2007- 25: 3815−3922.
- Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002−8:68−74.
- Shukla N., Trippett T. Non- Hodgkin’s lymphoma in children and adolescent: Curr.Onc.Rep.-2006,v.8№ 5,p.387−394-
- Siebert R, Matthiesen P, Harder S, et al. Application of interphase fluorescence in situ Hybridization for the detection of the Burkitt translocation t (8−14)(q24-q32) inB cell lymphomas. Blood. 1998- 91: 984−990.
- Spreafico F, Massimino M, Luksch R, et al. Intensive, very short-term chemotherapy for advanced Burkitt’s lymphoma in children. J Clin Oncol.2002−20:2783−2788.
- Stansfeld AG, Diebold J. Upated Kiel classification for lymphomas. Lancet. 1998- 1:292-
- Takano Y., Saegusa M., et al: Apoptosis and proliferative activity of Non-Hodgkin's lymphomas? comparison with expression of bcl2, p53 and c-MYC proteins.Pathlnt. 1997−47:90−94-
- Thomas DA, Faderl S, O’Brien S, et al: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569−1580, 2006
- Tudor G, Aguilera A, Halverson DO, et al: Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ 7:574−586, 2000
- Hoefer, E. Landmann, A. Reiter et al Sero-epidemiological studies for herpes viruses in children and adolescents with non-hodgkins lymphoma hr central Europe. 2002, Hematology Meeting Report 2009−3(5)|1|
- Van Krieken JH, Langerak AW, Macintyre EA, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98−3936. Leukemia. 2007−21: 201−206.
- Ventura R, Martin-Subero J, Jones M, et al. FISH analysis for thedetection" of lymphoma-associated chromosomal abnormalities in routine paraffiniembedded tissue. J Mol Diagn. In press.
- Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated. with CHOP or R-CHOP: a prospective correlative study. Blood.2006−107: 4207−4213.
- Woessmann W, Seidemann K, Mann G, et al. The impact of themethotrexate administration schedule and dose in the treatment of children and149adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005−105: 948−958.
- Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003- 82:160−165.
- Zium P., Juweid M. The role of FDG-PET scans in patients with lymphoma: Blood, 2007, v. 110,№ 10,p.3 507−3716-